Citations

Clear

2 citation(s) found for "Shah, Nalini".

Genotype-specific neoplastic risk profiles in patients with VHL disease
Ganner, Athina , Sekula, Peggy , Schiavi, Francesca , Joo, Julia H. , Sansó, Gabriela , Almeida, Madson Q. , Knoblauch, Anna Laura, Gizaw, Christine Julia, Krzystolik, Karol , Astheimer, Sophie, Vieites, Ana , Donegan, Diane , Simsir, Ilgin Yildirim , Bandgar, Tushar , Pawlaczek, Agnieszka, Zandee, Wouter T. , Kater, Cláudio E. , Qi, Xiao-Ping , Deutschbein, Timo , Dallagnol, Tabatha Nakakogue , Yukina, Marina, Baudrand, René , Andreescu, Corina , Kunavisarut, Tada , Ishak, Nur Diana Binte , Horn, Xavier Le Guillon, Shutler, Gemma, Jovanović, Milan , Calissendorf, Jan, Circosta, Francesco , Bugalho, Maria João , Corssmit, Eleonora Pm, Goldmann, Andrea , Zovato, Stefania , Santana, Lucas Santos de , Freitas-Castro, Felipe , Rothermund, Christy A, Zimmermann, Josa, Aycut, Ayca, Vroonen, Laurent , Krauß, Tobias , Taschner, Christian , Ruf, Juri , Gläsker, Sven , Bucher, Felicitas , Agostini, Hansjürgen , Jilg, Cordula A. , Schultze‐Seemann, Wolfgang, Bausch, Birke, Bergfeld, Antonia, Rhein, Kilian , Fang, Xu-Dong , Kotsis, Fruzsina , Schäfer, Tobias, Links, Thera P. , Makay, Özer , Fagundes, Gustavo Freitas Cardoso, Shah, Nalini , Barontini, Marta, Larsson, Catharina , Januszewicz, Andrzej , Lima, José Viana , Cybulski, Cezary, Walz, Martin K. , Koettgen, Anna, Neumann, Hartmut P.H., Neumann‐Haefelin, Elke , Köttgen, Anna , Yukina, M. Yu. , Sekula, Peggy , Almeida, Madson Q , Juhlin, Carl Christofer , Ngeow, Joanne , Eng, Charis , Baudrand, Rene , Ferrara, Alfonso Massimiliano , Steiert, Christine , Achatz, Maria Isabel , Hundsberger, Thomas , Lubiński, Jan , Hasse-Lazar, Kornelia , Yu, Kai , Rostomyan, Liliya , Remde, Hanna , Horn, Xavier Le Guillou , Jovanovic, Milan, Pęczkowska, Mariola , Calissendorff, Jan , Gimm, Oliver , Quinkler, Marcus , Watutantrige‐Fernando, Sara , Rothermundt, Christian Alexander , Zimmermann, Josa, Durmaz, Asude , Klingler, Jan‐Helge , Lang, Stefan Johann , Bergfeld, Antonia, Uslar, Thomas , Concistrè, Antonio , Juhlin, C. Christofer , Rocha, José Cláudio Casali da , Petramala, Luigi , Tsoy, U. A. , Grineva, Elena , Fagundes, Gustavo F C , Ngeow, Joanne , Opocher, Giuseppe , Wohllk, Nelson , Letizia, Claudio , Donatini, Gianluca , Maher, Eamonn R. , Beltsevich, D. G. , Bancos, Irina , Eng, Charis

Mayo Clinic

Endocrine-Related Cancer | April 9, 2025 | Volume: 32 | Issue: 5 | Pages: No page available

10.1530/erc-24-0260 | PMID 40202835 Get It

Abstract Hereditary tumor predisposition syndromes pose a challenge for early detection and timely treatment of tumors. In von Hippel–Lindau disease, desirable personalized surveillance programs are lacking due to insufficient data on genotype-specific risk profiles of individual mutations. To describe neoplastic risk profiles for carriers of pathogenic and likely pathogenic VHL germline mutations, our observational study recruited 1,350 participants from 40 centers worldwide. 432 different VHL germline mutations were observed, with p.Asn78Ser, p.Arg161Ter, p.Arg161Gln, p.Arg167Gln, p.Arg167Trp and p.Tyr98His being the six most frequent, occurring in a total of 493 carriers (36.5%) and in ≥30 patients each. Age-related penetrance risks for retinal hemangioblastoma, central nervous system hemangioblastoma, renal cell carcinoma, pancreatic neuroendocrine tumors and pheochromocytoma/paraganglioma in carriers of the most frequent VHL mutations were assessed. In addition, the number of organs affected, the frequency of surgery and the outcome are reported. Pairwise comparisons of the age-dependent tumor penetrance of these six mutations showed that 47 out of 90 pairs were significantly different. The most significant associations were found in p.Tyr98His (n = 19), followed by p.Arg161Ter (n = 10). All pairwise comparisons of mutations affecting different codons showed at least one significant (P < 0.05) difference, except for p.Asn78Ser vs p.Arg161Ter. Thus, tumor risk varied by VHL mutation type and location, but did not differ between the truncating mutation p.Arg161Ter and the missense mutation p.Asn78Ser. Our study demonstrates the importance of mutation-specific phenotype prediction. With appropriate validation, the data have important implications for risk assessment and decision making in tumor prevention for carriers of the respective VHL mutations.
Potent Neutralization of Staphylococcal Enterotoxin B by Synergistic Action of Chimeric Antibodies
Tilahun, Mulualem E., Rajagopalan, Govindarajan , Shah-Mahoney, Nalini, Lawlor, Rebecca, Tilahun, Ashenafi Y. , Xie, Chen , Natarajan, Kannan , Margulies, David H. , Ratner, David I., Osborne, Barbara A. , Goldsby, Richard A.

Mayo Clinic

Infection and Immunity | March 23, 2010 | Volume: 78 | Issue: 6 | Pages: 2801-2811

10.1128/iai.01121-09 | PMID 20308304 Get It

ABSTRACTStaphylococcal enterotoxin B (SEB), a shock-inducing exotoxin synthesized byStaphylococcus aureus, is an important cause of food poisoning and is a class B bioterrorism agent. SEB mediates antigen-independent activation of a major subset of the T-cell population by cross-linking T-cell receptors (TCRs) with class II major histocompatibility complex (MHC-II) molecules of antigen-presenting cells, resulting in the induction of antigen independent proliferation and cytokine secretion by a significant fraction of the T-cell population. Neutralizing antibodies inhibit SEB-mediated T-cell activation by blocking the toxin's interaction with the TCR or MHC-II and provide protection against the debilitating effects of this superantigen. We derived and searched a set of monoclonal mouse anti-SEB antibodies to identify neutralizing anti-SEB antibodies that bind to different sites on the toxin. A pair of non-cross-reactive, neutralizing anti-SEB monoclonal antibodies (MAbs) was found, and a combination of these antibodies inhibited SEB-induced T-cell proliferation in a synergistic rather than merely additive manner. In order to engineer antibodies more suitable than mouse MAbs for use in humans, the genes encoding the VL and VH gene segments of a synergistically acting pair of mouse MAbs were grafted, respectively, onto genes encoding the constant regions of human Igκ and human IgG1, transfected into mammalian cells, and used to generate chimeric versions of these antibodies that had affinity and neutralization profiles essentially identical to their mouse counterparts. When tested in cultures of human peripheral blood mononuclear cells or splenocytes derived from HLA-DR3 transgenic mice, the chimeric human-mouse antibodies synergistically neutralized SEB-induced T-cell activation and cytokine production.